The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression
Brain-derived neurotrophic factor (BDNF) is a growth factor synthesized in the cell bodies of neurons and glia, which affects neuronal maturation, the survival of nervous system, and synaptic plasticity. BDNF play an important role in the pathophysiology of major depression (MD). The serum BDNF leve...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/2/584 |
| _version_ | 1797622169232998400 |
|---|---|
| author | Reiji Yoshimura Naomichi Okamoto Enkmurun Chibaatar Tomoya Natsuyama Atsuko Ikenouchi |
| author_facet | Reiji Yoshimura Naomichi Okamoto Enkmurun Chibaatar Tomoya Natsuyama Atsuko Ikenouchi |
| author_sort | Reiji Yoshimura |
| collection | DOAJ |
| description | Brain-derived neurotrophic factor (BDNF) is a growth factor synthesized in the cell bodies of neurons and glia, which affects neuronal maturation, the survival of nervous system, and synaptic plasticity. BDNF play an important role in the pathophysiology of major depression (MD). The serum BDNF levels changed over time, or with the improvement in depressive symptoms. However, the change of serum BDNF during pharmacotherapy remains obscure in MDD. In particular, the changes in serum BDNF associated with pharmacotherapy have not yet been fully elucidated. The present study aimed to compare the changes in serum BDNF concentrations in first-episode, drug-naive patients with MD treated with antidepressants between treatment-response and treatment-nonresponse groups. The study included 35 inpatients and outpatients composed of 15 males and 20 females aged 36.7 ± 6.8 years at the Department of Psychiatry of our University Hospital. All patients met the DSM-5 diagnostic criteria for MD. The antidepressants administered included paroxetine, duloxetine, and escitalopram. Severity of depressive state was assessed using the 17-item HAMD before and 8 weeks after drug administration. Responders were defined as those whose total HAMD scores at 8 weeks had decreased by 50% or more compared to those before drug administration, while non-responders were those whose total HAMD scores had decreased by less than 50%. Here we showed that serum BDNF levels were not significantly different at any point between the two groups. The responder group, but not the non-responder group, showed statistically significant changes in serum BDNF 0 and serum BDNF 8. The results suggest that the changes of serum BDNF might differ between the two groups. The measurement of serum BDNF has the potential to be a useful predictor of pharmacotherapy in patients with first-episode, drug-naïve MD. |
| first_indexed | 2024-03-11T09:07:29Z |
| format | Article |
| id | doaj.art-f621f7cbd1184b12b9b4f826039407e4 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T09:07:29Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-f621f7cbd1184b12b9b4f826039407e42023-11-16T19:20:23ZengMDPI AGBiomedicines2227-90592023-02-0111258410.3390/biomedicines11020584The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major DepressionReiji Yoshimura0Naomichi Okamoto1Enkmurun Chibaatar2Tomoya Natsuyama3Atsuko Ikenouchi4Department of Psychiatry, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Fukuoka, JapanDepartment of Psychiatry, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Fukuoka, JapanDepartment of Psychiatry, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Fukuoka, JapanDepartment of Psychiatry, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Fukuoka, JapanDepartment of Psychiatry, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu 8078555, Fukuoka, JapanBrain-derived neurotrophic factor (BDNF) is a growth factor synthesized in the cell bodies of neurons and glia, which affects neuronal maturation, the survival of nervous system, and synaptic plasticity. BDNF play an important role in the pathophysiology of major depression (MD). The serum BDNF levels changed over time, or with the improvement in depressive symptoms. However, the change of serum BDNF during pharmacotherapy remains obscure in MDD. In particular, the changes in serum BDNF associated with pharmacotherapy have not yet been fully elucidated. The present study aimed to compare the changes in serum BDNF concentrations in first-episode, drug-naive patients with MD treated with antidepressants between treatment-response and treatment-nonresponse groups. The study included 35 inpatients and outpatients composed of 15 males and 20 females aged 36.7 ± 6.8 years at the Department of Psychiatry of our University Hospital. All patients met the DSM-5 diagnostic criteria for MD. The antidepressants administered included paroxetine, duloxetine, and escitalopram. Severity of depressive state was assessed using the 17-item HAMD before and 8 weeks after drug administration. Responders were defined as those whose total HAMD scores at 8 weeks had decreased by 50% or more compared to those before drug administration, while non-responders were those whose total HAMD scores had decreased by less than 50%. Here we showed that serum BDNF levels were not significantly different at any point between the two groups. The responder group, but not the non-responder group, showed statistically significant changes in serum BDNF 0 and serum BDNF 8. The results suggest that the changes of serum BDNF might differ between the two groups. The measurement of serum BDNF has the potential to be a useful predictor of pharmacotherapy in patients with first-episode, drug-naïve MD.https://www.mdpi.com/2227-9059/11/2/584brain-derived neurotrophic factorserumtrajectorymajor depressionfirst-episodedrug-naïve |
| spellingShingle | Reiji Yoshimura Naomichi Okamoto Enkmurun Chibaatar Tomoya Natsuyama Atsuko Ikenouchi The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression Biomedicines brain-derived neurotrophic factor serum trajectory major depression first-episode drug-naïve |
| title | The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression |
| title_full | The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression |
| title_fullStr | The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression |
| title_full_unstemmed | The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression |
| title_short | The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression |
| title_sort | serum brain derived neurotrophic factor increases in serotonin reuptake inhibitor responders patients with first episode drug naive major depression |
| topic | brain-derived neurotrophic factor serum trajectory major depression first-episode drug-naïve |
| url | https://www.mdpi.com/2227-9059/11/2/584 |
| work_keys_str_mv | AT reijiyoshimura theserumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT naomichiokamoto theserumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT enkmurunchibaatar theserumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT tomoyanatsuyama theserumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT atsukoikenouchi theserumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT reijiyoshimura serumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT naomichiokamoto serumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT enkmurunchibaatar serumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT tomoyanatsuyama serumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression AT atsukoikenouchi serumbrainderivedneurotrophicfactorincreasesinserotoninreuptakeinhibitorresponderspatientswithfirstepisodedrugnaivemajordepression |